About eurofins scientific se - ERFSF
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.
ERFSF At a Glance
Eurofins Scientific SE
23 Val Fleuri
Luxembourg, Luxembourg 1526
| Phone | 352-26-18-53-20 | Revenue | 8.23B | |
| Industry | Miscellaneous Commercial Services | Net Income | 536.07M | |
| Sector | Commercial Services | 2025 Sales Growth | 9.513% | |
| Fiscal Year-end | 12 / 2026 | Employees | 65,000 | |
| View SEC Filings |
ERFSF Valuation
| P/E Current | 27.631 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 24.607 |
| Price to Sales Ratio | 1.664 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | 9.38 |
| Enterprise Value to EBITDA | 11.952 |
| Enterprise Value to Sales | 2.331 |
| Total Debt to Enterprise Value | 0.332 |
ERFSF Efficiency
| Revenue/Employee | 126,678.534 |
| Income Per Employee | 8,247.30 |
| Receivables Turnover | 4.562 |
| Total Asset Turnover | 0.681 |
ERFSF Liquidity
| Current Ratio | 1.092 |
| Quick Ratio | 1.035 |
| Cash Ratio | 0.326 |
ERFSF Profitability
| Gross Margin | 10.869 |
| Operating Margin | 10.869 |
| Pretax Margin | 8.964 |
| Net Margin | 6.51 |
| Return on Assets | 4.435 |
| Return on Equity | 12.389 |
| Return on Total Capital | 5.086 |
| Return on Invested Capital | 5.809 |
ERFSF Capital Structure
| Total Debt to Total Equity | 153.316 |
| Total Debt to Total Capital | 60.524 |
| Total Debt to Total Assets | 49.449 |
| Long-Term Debt to Equity | 132.797 |
| Long-Term Debt to Total Capital | 52.423 |